Focinvez (fosaprepitant dimeglumine) NDC 82449-231

NDC codes

FDA NDC Directory

Product NDC (as listed)82449-231Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82449-0231Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82449-231-01	82449023101	1 VIAL, SINGLE-DOSE in 1 CARTON (82449-231-01) / 50 mL in 1 VIAL, SINGLE-DOSEMarketed from Jun 26, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Focinvez
Generic name (nonproprietary): fosaprepitant dimeglumine
Active ingredients: Fosaprepitant dimeglumine — 150 mg/50mL
Dosage form: Injection
Route: Intravenous
Labeler: Steriscience Specialties Private Limited
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 216686
Marketing start: Jun 26, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
Identifiers: Product ID 82449-231_4e50b25f-abb3-dcb2-e063-6394a90a2517SPL ID 4e50b25f-abb3-dcb2-e063-6394a90a2517SPL set ID 18a60093-cec8-1b8c-e063-6394a90a8902RxCUI 2664065, 2664071UNII D35FM8T64X
Pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N482449023101 followed by a unit qualifier and the quantity

Package 82449-0231-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026.

Indications (excerpt from the label)

FOCINVEZ, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use FOCINVEZ has not been studied for the treatment of established nausea and vomiting. FOCINVEZ is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other a…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 216686

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 216686
Product	Strength	Form · route	Labeler	Product NDC
Focinvezfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/50mL	InjectionIntravenous	Amneal Pharmaceuticals LLC	70121-2631